Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +548.7%
S&P 500 total return (same window) +37.0%
Excess return +511.7%

Annualized: +346.7% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 100.0%

Full portfolio 2 positions

05
Type Streak 8Q trend
MAZE Maze Therapeutics, Inc. - Common Stock $133,502,907 52.63% 4,473,958 $-44,739
TNGX Tango Therapeutics, Inc. - Common Stock $120,181,383 47.37% 6,374,574 $-13,174,705

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
TNGX Price move only +0 -$13.2M
MAZE Price move only +0 -$45K

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
PLRX Sept. 30, 2025 2,132,867 $2,474,126 -30.1%